Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IntraPace Plans Anti-Obesity Stomach Stimulator Pivotal Trial

This article was originally published in The Gray Sheet

Executive Summary

IntraPace is in discussions with FDA about an investigational device exemption for its abiliti anti-obesity stomach pacemaker system, and hopes to begin a U.S. pivotal trial by early 2012, according to the company.

You may also be interested in...



Obesity 2015: Less Invasive Options Will Drive Growth In Market Hungry For Solutions

Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.

MetaCure Implant For Type 2 Diabetes: Overseas Trials To Wrap Up By 2012

MetaCure plans to wrap up three overseas trials by the end of 2012 for its DIAMOND electrostimulator implant for type 2 diabetes in obese patients and will begin a pivotal U.S. trial within the next couple of years to support a PMA submission for type 2 diabetes.

MetaCure Implant For Type 2 Diabetes: Overseas Trials To Wrap Up By 2012

MetaCure plans to wrap up three overseas trials by the end of 2012 for its DIAMOND electrostimulator implant for type 2 diabetes in obese patients and will begin a pivotal U.S. trial within the next couple of years to support a PMA submission for type 2 diabetes.

Related Content

Topics

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel